CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics

1. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017; 18: 197-236. 
2. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 1987; 169: 5429-5433. 
3. Zhang B. CRISPR/Cas gene therapy. J Cell Physiol 2021; 236: 2459-2481. 
4. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 2005; 151: 2551-2561. 
5. Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 2018; 556: 57-63. 
6. Makarova KS, Grishin N V, Shabalina SA, Wolf YI, Koonin E V. A putative RNA-interference-based immune system in prokaryotes: Computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct 2006; 1: 7-33. 
7. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007; 315: 1709-1712. 
8. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 2010; 468: 67-71. 
9. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821. 
10. Hu Y, Liu L, Jiang Q, Fang W, Chen Y, Hong Y, et al. CRISPR/Cas9: A powerful tool in colorectal cancer research. J Exp Clin Cancer Res 2023; 42: 308-327. 
11. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 2013; 41: 7429-7437. 
12. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature 2016; 539: 479. 
13. Liu Y, Zou RS, He S, Nihongaki Y, Li X, Razavi S, et al. Very fast CRISPR on demand. Science 2020; 368: 1265-1269. 
14. Xiong X, Chen M, Lim WA, Zhao D, Qi LS. CRISPR/Cas9 for human genome engineering and disease research. Annu Rev Genomics Hum Genet 2016; 17: 131-154. 
15. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014; 15: 321-334. 
16. Ringel T, Frey N, Ringnalda F, Janjuha S, Cherkaoui S, Butz S, et al. Genome-scale CRISPR screening in human intestinal organoids identifies drivers of TGF-β resistance. Cell Stem Cell 2020; 26: 431-440. 
17. Michels BE, Mosa MH, Streibl BI, Zhan T, Menche C, Abou-El-Ardat K, et al. Pooled in vitro and in vivo CRISPR-Cas9 screening identifies tumor suppressors in human colon organoids. Cell Stem Cell 2020; 26: 782-792.
18. Wang D, Prager BC, Gimple RC, Aguilar B, Alizadeh D, Tang H, et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov 2021;11: 1192-1211. 
19. Emami A, Mahdavi Sharif P, Rezaei N. KRAS mutations in colorectal cancer: Impacts on tumor microenvironment and therapeutic implications. Expert Opin Ther Targets 2025; 5: 361-383. 
20. Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A, et al. The role of KRAS mutations in colorectal cancer: Biological insights, clinical implications, and future therapeutic perspectives. Cancers 2025; 17: 428-449. 
21. Shao M, Xu TR, Chen CS. The big bang of genome editing technology: development and application of the  CRISPR/Cas9 system in disease animal models. Dongwuxue Yanjiu 2016; 37: 191-204. 
22. Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics 2021; 15: 353-361. 
23. Jiang F, Doudna JA. CRISPR–Cas9 structures and mechanisms. Annu Rev Biophys 2017; 46: 505-529. 
24. Mei Y, Wang Y, Chen H, Sun ZS, Ju XD. Recent progress in CRISPR/Cas9 technology. J Genet Genomics 2016; 43: 63-75. 
25. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 1258096. 
26. Beck AC, Cho E, White JR, Paemka L, Li T, Gu VW, et al. AP-2α regulates S-phase and is a marker for sensitivity to PI3K inhibitor  buparlisib in colon cancer. Mol Cancer Res 2021; 19: 1156-1167. 
27. Meng H, Nan M, Li Y, Ding Y, Yin Y, Zhang M. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Front Endocrinol 2023; 14: 1148412-1148433. 
28. Han T, Schatoff EM, Murphy C, Zafra MP, Wilkinson JE, Elemento O, et al. R-Spondin chromosome rearrangements drive Wnt-dependent tumour initiation and  maintenance in the intestine. Nat Commun 2017; 8: 15945-15957. 
29. Liu Q, Xin C, Chen Y, Yang J, Chen Y, Zhang W, et al. PUM1 is overexpressed in colon cancer cells with acquired resistance to  cetuximab. Front cell Dev Biol 2021; 9: 696558-696569. 
30. Liu HH, Lee CH, Hsieh YC, Hsu DW, Cho EC. Multiple myeloma driving factor WHSC1 is a transcription target of oncogene HMGA2  that facilitates colon cancer proliferation and metastasis. Biochem Biophys Res Commun 2021; 567: 183-189. 
31. Liu Z, Li Y, Wang S, Wang Y, Sui M, Liu J, et al. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. J Exp Clin Cancer Res 2025; 44: 70-90. 
32. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer:  Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol  Off J Am Soc  Clin Oncol 2010; 28: 466-474. 
33. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation  variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol  Off J Eur Soc Med  Oncol 2016; 27: 1746-1753. 
34. Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Ann Oncol Off J Eur Soc Med Oncol 2017; 28: 562-568. 
35. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, et al. Epidermal growth factor receptor gene copy number, K-ras mutation and  pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol  Off J Eur Soc Med  Oncol 2009; 20: 469-474. 
36. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus  irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721. 
37. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in  colorectal cancer. Nature 2012; 486: 532-536. 
38. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in  metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603. 
39. Liu H, Liang Z, Cheng S, Huang L, Li W, Zhou C, et al. Mutant KRAS drives immune evasion by sensitizing cytotoxic T-Cells to  activation-induced cell death in colorectal cancer. Adv Sci (Weinheim) 2023; 10: e2203757-2203772. 
40. Lal N, White BS, Goussous G, Pickles O, Mason MJ, Beggs AD, et al. KRAS mutation and consensus molecular subtypes 2 and 3 are independently  associated with reduced immune infiltration and reactivity in colorectal cancer. Clin cancer Res 2018; 24: 224-233. 
41.  Arroyo-Olarte R, Mejía-Muñoz A, León-Cabrera S. Expanded alternatives of CRISPR–Cas9 applications in immunotherapy of colorectal cancer. Mol Diagn Ther 2024; 28: 69-86. 
42. Takeda H, Kataoka S, Nakayama M, Ali MAE, Oshima H, Yamamoto D, et al. CRISPR-Cas9–mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc Natl Acad Sci 2019; 116: 15635-15644. 
43. D’Antonio L, Fieni C, Ciummo SL, Vespa S, Lotti L, Sorrentino C, et al. Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome  editing inhibits their oncogenicity and improves host survival. J Immunother Cancer 2023; 11: e006056-e006073. 
44. Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in colorectal cancer and its implication for therapy. Cancers (Basel) 2021;13: 2296-2320. 
45. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 2020; 12: 738-757. 
46. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 2021; 14: 45-74. 
47. Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D, et al. CRISPR/Cas9 gene editing: A new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett 2022; 27: 49-78. 
48. Wu M, Ma W, Lv G, Wang X, Li C, Chen X, et al. DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening. NPJ Precis Oncol 2024; 8: 253-264. 
49. Ravichandran M, Maddalo D. Applications of CRISPR-Cas9 for advancing precision medicine in oncology: From target discovery to disease modeling. Front Genet 2023; 14: 127399-127411. 
50. Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome  editing. Nature 2014; 516: 428-431. 
51. Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 2018; 561: 416-419. 
52. Hartmann O, Reissland M, Maier CR, Fischer T, Prieto-Garcia C, Baluapuri A, et al. Implementation of CRISPR/Cas9 genome editing to generate murine lung cancer models that depict the mutational landscape of human disease. Front Cell Dev Biol 2021; 9: 641618-641634. 
53. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding  and retargeting of adeno-associated viruses. J Virol 2008; 82: 5887-5911. 
54. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280-10288. 
55. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of  oncogenic K-ras. Genes Dev 2001; 15: 3243-3248. 
56. Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, et al. Prevalence of anti-adeno-associated virus immune responses in international  cohorts of healthy donors. Mol Ther Methods Clin Dev 2019; 14: 126-133. 
57. Weber T. Anti-AAV antibodies in AAV gene therapy: Current challenges and possible solutions. Front Immunol 2021; 12: 658399-658404. 
58. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that  affect transduction and neutralization. J Virol 2006; 80: 821-834. 
59. Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, Montus M-F, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing  factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 2011; 19: 2084-2091. 
60. Bertin B, Veron P, Leborgne C, Deschamps J-Y, Moullec S, Fromes Y, et al. Capsid-specific removal of circulating antibodies to adeno-associated virus  vectors. Sci Rep 2020; 10: 864-875. 
61. Orlowski A, Katz MG, Gubara SM, Fargnoli AS, Fish KM, Weber T. Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption. Mol Ther Methods Clin Dev 2020; 16: 192-203. 
62. Vincents B, von Pawel-Rammingen U, Björck L, Abrahamson M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that  it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 2004; 43: 15540-15549. 
63. Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of  anti-AAV neutralizing antibodies. Nat Med 2020; 26: 1096-1101. 
64. Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading  enzyme. JCI Insight 2020; 5: e139881-e139892. 
65. Yang Z-X, Fu Y-W, Zhao J-J, Zhang F, Li S-A, Zhao M, et al. Superior fidelity and distinct editing outcomes of SaCas9 compared with SpCas9 in genome editing. Genomics Proteomics Bioinformatics 2023; 21: 1206-1220. 
66. Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar V V, Zheng Z, et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol 2015; 33: 1293-1298. 
67. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021; 385: 493-502. 
68. Yue N, Xu H, Xu J, Zhu M, Zhang Y, Tian C-M, et al. Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives. Mol Ther Oncolytics 2023; 30: 193-215. 
69. Zhang S, Wang Y, Mao D, Wang Y, Zhang H, Pan Y, et al. Current trends of clinical trials involving CRISPR/Cas systems. Front Med 2023; 10: 1292452-1292470. 
70. Ma L, Ma Y, Gao Q, Liu S, Zhu Z, Shi X, et al. Mulberry leaf lipid nanoparticles: A naturally targeted CRISPR/Cas9 oral delivery platform for alleviation of colon diseases. Small 2024; 20: e2307247. 
71. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015; 21: 256-262. 
72. Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas system: The current and emerging translational landscape. Cells 2023; 12: 1103-1142. 
73. Li Y, Li C, Yan J, Liao Y, Qin C, Wang L, et al. Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer. Biomaterials 2024; 309: 122573. 
74. Wan T, Pan Q, Liu C, Guo J, Li B, Yan X, et al. A duplex CRISPR-Cas9 ribonucleoprotein nanomedicine for colorectal cancer gene therapy. Nano Lett 2021; 21: 9761-9771. 
75. Feng Q, Li Q, Zhou H, Wang Z, Lin C, Jiang Z, et al. CRISPR technology in human diseases. MedComm 2024; 5: 672-743. 
76. Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol 2020; 38: 3638-3651. 
77. Zheng Z, Wieder T, Mauerer B, Schäfer L, Kesselring R, Braumüller H. T cells in colorectal cancer: Unravelling the function of different T cell subsets in the tumor microenvironment. Int J Mol Sci 2023; 24: 11673-11708. 
78. Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee J-KJ, et al. Multicenter international study of the consensus immunoscore for the prediction of relapse and survival in early-stage colon cancer. Cancers (Basel) 2023; 15: 418-437. 
79. Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer 2023; 23: 295-316. 
80. Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, et al. Plasticity of human CD4 T cell subsets. Front Immunol 2014; 5: 630-640. 
81. Bell HN, Huber AK, Singhal R, Korimerla N, Rebernick RJ, Kumar R, et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab 2023; 35: 134-149. 
82. Bhaumik S, Basu R. Cellular and molecular dynamics of Th17 differentiation and its developmental  plasticity in the intestinal immune response. Front Immunol 2017; 8: 254-274. 
83. Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, et al. CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 2023; 618: 1033-1040. 
84. Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. Front Immunol 2017; 8: 194-201. 
85. Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of  colitis. Proc Natl Acad Sci U S A 2015; 112: 7061-7066. 
86. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011; 12: 255-263. 
87. Wu T, Cui L, Liang Z, Liu C, Liu Y, Li J. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clin Immunol 2013; 147:38-39. 
88. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491: 259-263. 
89. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210: 917-931. 
90. Perez LG, Kempski J, McGee HM, Pelzcar P, Agalioti T, Giannou A, et al. TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. Nat Commun 2020; 11: 2608-2622. 
91. Sawant DV, Vignali DAA. Once a Treg, always a Treg? Immunol Rev 2014; 259: 173-191. 
92. Yang H, Li Q, Chen X, Weng M, Huang Y, Chen Q, et al. Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer. Nat Commun 2024; 15: 4296-4317. 
93. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020; 20: 662-680. 
94. Rentschler M, Braumüller H, Briquez PS, Wieder T. Cytokine-induced senescence in the tumor microenvironment and its effects on anti-tumor immune responses. Cancers (Basel) 2022; 14: 1364-1386. 
95. Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 2020; 11: 1335-1354. 
96. Wozniakova M, Skarda J, Raska M. The role of tumor microenvironment and immune response in colorectal cancer  development and prognosis. Pathol Oncol Res 2022; 28: 1610502-1610514. 
97. Li H, Wang Y, Fan R, Lv H, Sun H, Xie H, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after  biliary drainage. Drug Des Devel Ther 2016; 10: 2173-2180. 
98. Braumüller H, Mauerer B, Andris J, Berlin C, Wieder T, Kesselring R. The cytokine network in colorectal cancer: Implications for new treatment strategies. Cells 2023; 12: 138-173. 
99. Li H, Jiang Y, Wang Y, Lv H, Xie H, Yang G, et al. The effects of warfarin on the pharmacokinetics of senkyunolide I in a rat model  of biliary drainage after administration of chuanxiong.Front Pharmacol 2018; 9: 1461-1469. 
100. Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W, et al. TGF-β suppresses type 2 immunity to cancer. Nature 2020; 587: 115-120. 
101. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat Med. 2022; 28: 1189-1198. 
102. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018; 554: 538-543. 
103. Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: Where are we  after 40 years? Cancer Metastasis Rev 2020; 39: 969-987. 
104. Katz SC, Moody AE, Guha P, Hardaway JC, Prince E, LaPorte J, et al. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study  utilizing pressure enabled drug delivery. J Immunother Cancer 2020; 8: e001097-1104. 
105. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356. 
106. Zhang B, Wang Y, Wang S, Tang Y, Li Z, Lin L, et al. Precise RNA editing: Cascade self‐uncloaking dual‐prodrug nanoassemblies based on CRISPR/Cas13a for pleiotropic immunotherapy of PD‐L1‐resistant colorectal cancer. Adv Funct Mater 2023; 33: 2305630. 
107. Zhang N, Li J, Yu J, Wan Y, Zhang C, Zhang H, et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment. Virus Res 2023; 323: 198979-198990. 
108. Gao L, Yang L, Zhang S, Ge Z, Su M, Shi Y, et al. Engineering NK-92 cell by upregulating CXCR2 and IL-2 Via CRISPR-Cas9 improves its antitumor effects as cellular immunotherapy for human colon cancer. J Interf cytokine Res 2021; 41: 450-460. 
109. Zhu D, Kim WJ, Lee H, Bao X, Kim P. Engineering CAR‐T therapeutics for enhanced solid tumor targeting. Adv Mater 2025:e241488. 
110. Han HA, Pang JKS, Soh B-S. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med 2020; 98: 615-632. 
111. Kay MA. State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet 2011; 12: 316-328. 
112. Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors. Gene Ther 2010; 17: 295-304. 
113. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of  SCID-X1. J Clin Invest 2008; 118: 3132-3142. 
114. Xu A, Deng F, Chen Y, Kong Y, Pan L, Liao Q, et al. NF-κB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother 2020; 130: 110525-110537. 
115. Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010; 18: 87-92. 
116. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 2015; 33: 102-106. 
117. Senís E, Fatouros C, Große S, Wiedtke E, Niopek D, Mueller A-K, et al. CRISPR/Cas9-mediated genome engineering: An adeno-associated viral (AAV) vector  toolbox. Biotechnol J 2014; 9: 1402-1412. 
118. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 2014; 156: 935-949. 
119. Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al. Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer  cells by regulating PI3K/AKT/mTOR signaling pathway. Front Pharmacol 2022; 13: 901559-901568. 
120. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186-191. 
121. Friedland AE, Baral R, Singhal P, Loveluck K, Shen S, Sanchez M, et al. Characterization of Staphylococcus aureus Cas9: A smaller Cas9 for all-in-one  adeno-associated virus delivery and paired nickase applications. Genome Biol 2015; 16: 257-267. 
122. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4: 581-593. 
123. Wang M, Zuris JA, Meng F, Rees H, Sun S, Deng P, et al. Efficient delivery of genome-editing proteins using bioreducible lipid  nanoparticles. Proc Natl Acad Sci U S A 2016; 113: 2868-2873. 
124. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based  genome editing in vitro and in vivo. Nat Biotechnol 2015; 33: 73-80. 
125. Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces  homology-directed DNA repair. Nat Biomed Eng 2017; 1: 889-901. 
126. Wu B, Wang Z-X, Xie H, Xie P-L. Dimethyl fumarate augments anticancer activity of ångstrom silver particles in myeloma cells through NRF2 activation. Adv Ther 2025; 8: 2400363. 
127. Li L, He Z-Y, Wei X-W, Gao G-P, Wei Y-Q. Challenges in CRISPR/CAS9 delivery: Potential roles of nonviral vectors. Hum Gene Ther 2015; 26: 452-462. 
128. Yang H, He C, Bi Y, Zhu X, Deng D, Ran T, et al. Synergistic effect of VEGF and SDF-1α in endothelial progenitor cells and  vascular smooth muscle cells. Front Pharmacol 2022; 13: 914347-914358. 
129. Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015; 9: GE01-6. 
130. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med 2018; 20: e3015. 
131. Li H, Zhou Y, Liao L, Tan H, Li Y, Li Z, et al. Pharmacokinetics effects of chuanxiong rhizoma on warfarin in pseudo germ-free  rats. Front Pharmacol 2022; 13: 1022567-1022578. 
132. D. GJ, Ed G, Jorg T, Justin K, Marianna F, L. MM, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021; 385: 493-502. 
133. Zhang Z, Zhang S, Wong HT, Li D, Feng B. Targeted gene insertion: The cutting edge of CRISPR drug development with hemophilia as a highlight. BioDrugs 2024; 38: 369-385. 
134. Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of  purified Cas9 ribonucleoproteins. Genome Res 2014; 24: 1012-1019. 
135. Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 2015; 141: 769-784. 
136. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of  cancer therapeutics. Eur J Pharm Sci 2013; 48: 416-427. 
137. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000; 41: 147-162. 
138. He Z-Y, Zhang Y-G, Yang Y-H, Ma C-C, Wang P, Du W, et al. In vivo ovarian cancer gene therapy using CRISPR-Cas9. Hum Gene Ther 2018; 29: 223-233. 
139. Peng W, Chen L, Liu J. Celastrol inhibits gastric cancer cell proliferation, migration, and invasion via the FOXA1/CLDN4 axis. Toxicol Res (Camb) 2023; 12: 392-399. 
140. Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V. Transferrin and octaarginine modified dual-functional liposomes with improved  cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv 2018; 25: 517-532. 
141. Ahangar RM, Firuzpour F, Aram C. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in a 50-year-old woman. Case Reports Clin Pract 2025; 9: 152-158. 
142. Papademetriou I, Vedula E, Charest J, Porter T. Effect of flow on targeting and penetration of angiopep-decorated nanoparticles  in a microfluidic model blood-brain barrier. PLoS One 2018; 13: e0205158-205176. 
143. Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, et al. Angiopep-conjugated poly (ethylene glycol)-co-poly (ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011; 32: 4293-4305. 
144. Kim JS, Shin DH, Kim J-S. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release 2018; 269: 245-257. 
145. Liang C, Li F, Wang L, Zhang Z-K, Wang C, He B, et al. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 2017; 147: 68-85. 
146. Salvi N, Abyzov A, Blackledge M. Analytical description of NMR relaxation highlights correlated dynamics in  intrinsically disordered proteins. Angew Chem Int Ed Engl 2017; 56: 14020-14024. 
147. Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nat Rev Drug Discov 2017; 16: 387-399. 
148. Silvius JR, Leventis R. A novel “Prebinding” strategy dramatically enhances sortase-mediated coupling of proteins to liposomes. Bioconjug Chem 2017; 28: 1271-1282. 
149. Koide H, Tsuchida H, Nakamoto M, Okishima A, Ariizumi S, Kiyokawa C, et al. Rational designing of an antidote nanoparticle decorated with abiotic polymer  ligands for capturing and neutralizing target toxins. J Control release 2017; 268: 335-342. 
150. Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 2020; 181: 136-150. 
151. Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin  nanoparticles enables successful vector re-administration. Nat Commun 2018; 9: 4098-4111. 
152. Anzalone A V, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019; 576: 149-157. 
153. Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol 2017; 216: 3799-3816. 
154. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat Nanotechnol 2020; 15: 313-320. 
155. Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. Biomaterials 2018; 171: 207-218. 
156. Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv 2020; 6: eabc9450-eabc9462. 
157. Yau EH, Kummetha IR, Lichinchi G, Tang R, Zhang Y, Rana TM. Genome-wide CRISPR screen for essential cell growth mediators in mutant KRAS  colorectal cancers. Cancer Res 2017; 77: 6330-6339. 
158. Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, et al. In vivo genome editing and organoid transplantation models of colorectal cancer  and metastasis. Nat Biotechnol 2017; 35: 569-576. 
159. Li Y, Li X, Qu J, Luo D, Hu Z. Cas9 mediated correction of β-catenin mutation and restoring the expression of protein phosphorylation in colon cancer HCT-116 cells decrease cell proliferation in vitro and hamper tumor growth in mice in vivo. Onco Targets Ther 2020; 13: 17-29. 
160. Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015; 521: 43-47. 
161. Pothuraju R, Rachagani S, Krishn SR, Chaudhary S, Nimmakayala RK, Siddiqui JA, et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and  chemoresistance. Mol Cancer 2020; 19: 37-51. 
162. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human  cells. Nat Biotechnol 2013; 31: 822-826. 
163. Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci 2021; 267: 118969. 
164. Sioson VA, Kim M, Joo J. Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomed Eng Lett 2021; 11: 217-233. 
165. Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and  applications in cancer therapy. Mol Cancer 2024; 23: 9-54. 
166. Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Alkhaleefah FK, Rahmani AH, et al. Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: An innovative strategy of cancer management. Cancer Commun 2022; 42: 1257-1287. 
167. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions  and complex rearrangements. Nat Biotechnol 2018; 36: 765-771. 
168. Chen JS, Dagdas YS, Kleinstiver BP, Welch MM, Sousa AA, Harrington LB, et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature 2017; 550: 407-410. 
169. Grünewald J, Zhou R, Garcia SP, Iyer S, Lareau CA, Aryee MJ, et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 2019; 569: 433-437. 
170. Takeda H, Kataoka S, Nakayama M, Ali MAE, Oshima H, Yamamoto D, et al. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides  functional validation for colorectal cancer driver genes. Proc Natl Acad Sci U S A 2019; 116: 15635-15644. 
171. Galon J, Bruni D. Tumor immunology and tumor evolution: Intertwined histories. Immunity 2020; 52: 55-81. 
172. Klemm F, Möckl A, Salamero-Boix A, Alekseeva T, Schäffer A, Schulz M, et al. Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. Nat Cancer 2021; 2: 1086-1101. 
173. Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov 2021; 11: 933-959. 
174. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 2019; 25: 249-254. 
175. Xu W, Zhang S, Qin H, Yao K. From bench to bedside: Cutting-edge applications of base editing and prime editing in precision medicine. J Transl Med 2024; 22: 1133-1176. 
176. Li R, Wang Y, Hu H, Tan Y, Ma Y. Metagenomic analysis reveals unexplored diversity of archaeal virome in the human gut. Nat Commun 2022; 13: 7978-7990. 
177. Huang S, Zhang Z, Tao W, Liu Y, Li X, Wang X, et al. Broadening prime editing toolkits using RNA-Pol-II-driven engineered pegRNA. Mol Ther 2022; 30: 2923-2932. 
178. Huang TP, Zhao KT, Miller SM, Gaudelli NM, Oakes BL, Fellmann C, et al. Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol 2019; 37: 626-631. 
179. Anzalone A V, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime  editors. Nat Biotechnol 2020; 38: 824-844. 
180. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA  cleavage. Nature 2016; 533: 420-424. 
181. Cho S-I, Lee S, Mok YG, Lim K, Lee J, Lee JM, et al. Targeted A-to-G base editing in human mitochondrial DNA with programmable  deaminases. Cell 2022; 185: 1764-1776. 
182. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys A V, Raguram A, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 2020; 583: 631-637. 
183. Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 2016; 353: aaf8729.
184. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 2017; 551: 464-471. 
185. Alanis-Lobato G, Zohren J, McCarthy A, Fogarty NME, Kubikova N, Hardman E, et al. Frequent loss of heterozygosity in CRISPR-Cas9-edited early human embryos. Proc Natl Acad Sci U S A 2021; 118: e2004832117-e2004832126.
186. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med 2018; 24: 939-946. 
187. Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 2018; 24: 927-930. 
188. Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet 2020; 52: 662-668. 
189. Tao J, Wang Q, Mendez-Dorantes C, Burns KH, Chiarle R. Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. Nat Commun 2022; 13: 3685-3702. 
190. Ferrari S, Jacob A, Beretta S, Unali G, Albano L, Vavassori V, et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol 2020; 38: 1298-1308. 
191. Song Y, Liu Z, Zhang Y, Chen M, Sui T, Lai L, et al. Large-fragment deletions induced by Cas9 cleavage while not in the BEs system. Mol Ther Nucleic Acids 2020; 21: 523-526. 
192. Gehrke JM, Cervantes O, Clement MK, Wu Y, Zeng J, Bauer DE, et al. An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nat Biotechnol 2018; 36: 977-982. 
193. Doman JL, Raguram A, Newby GA, Liu DR. Evaluation and minimization of Cas9-independent off-target DNA editing by  cytosine base editors. Nat Biotechnol 2020; 38: 620-628. 
194. Rees HA, Wilson C, Doman JL, Liu DR. Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci Adv 2019; 5: eaax5717-5727. 
195. Grünewald J, Zhou R, Iyer S, Lareau CA, Garcia SP, Aryee MJ, et al. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol 2019; 37: 1041-1048. 
196. Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR. Increasing the genome-targeting scope and precision of base editing with  engineered Cas9-cytidine deaminase fusions. Nat Biotechnol 2017; 35: 371-376. 
197. Nishimasu H, Shi X, Ishiguro S, Gao L, Hirano S, Okazaki S, et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 2018; 361: 1259-1262. 
198. Walton RT, Christie KA, Whittaker MN, Kleinstiver BP. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science 2020; 368: 290-296. 
199. Miller SM, Wang T, Randolph PB, Arbab M, Shen MW, Huang TP, et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat Biotechnol 2020; 38: 471-481. 
200. Sakata RC, Ishiguro S, Mori H, Tanaka M, Tatsuno K, Ueda H, et al. Base editors for simultaneous introduction of C-to-T and A-to-G mutations. Nat Biotechnol 2020; 38: 865-869. 
201. Grünewald J, Zhou R, Lareau CA, Garcia SP, Iyer S, Miller BR, et al. A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine  editing. Nat Biotechnol 2020; 38: 861-864. 
202. Zhang X, Zhu B, Chen L, Xie L, Yu W, Wang Y, et al. Dual base editor catalyzes both cytosine and adenine base conversions in human  cells. Nat Biotechnol 2020; 38: 856-860. 
203. Kurt IC, Zhou R, Iyer S, Garcia SP, Miller BR, Langner LM, et al. CRISPR C-to-G base editors for inducing targeted DNA transversions in human  cells. Nat Biotechnol 2021; 39: 41-46. 
204. Zhao D, Li J, Li S, Xin X, Hu M, Price MA, et al. Glycosylase base editors enable C-to-A and C-to-G base changes. Nat Biotechnol 2021; 39: 35-40. 
205. Chen L, Park JE, Paa P, Rajakumar PD, Prekop H-T, Chew YT, et al. Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins. Nat Commun 2021; 12: 1384-1391. 
206. Koblan LW, Arbab M, Shen MW, Hussmann JA, Anzalone A V, Doman JL, et al. Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning. Nat Biotechnol 2021; 39: 1414-1425. 
207. Chen L, Hong M, Luan C, Gao H, Ru G, Guo X, et al. Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in  mammalian cells and embryos. Nat Biotechnol 2024; 42: 638-650. 
208. Tong H, Wang X, Liu Y, Liu N, Li Y, Luo J, et al. Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase. Nat Biotechnol 2023; 41: 1080-1084. 
209. Tong H, Wang H, Wang X, Liu N, Li G, Wu D, et al. Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase. Nat Commun 2024; 15: 4897-4909. 
210. Hanna RE, Hegde M, Fagre CR, DeWeirdt PC, Sangree AK, Szegletes Z, et al. Massively parallel assessment of human variants with base editor screens. Cell 2021; 184: 1064-1080.
211. Zhao L, Liao M, Li L, Chen L, Zhang T, Li R. Cadmium activates the innate immune system through the AIM2 inflammasome. Chem Biol Interact 2024; 399: 111122. 
212. Rothgangl T, Dennis MK, Lin PJC, Oka R, Witzigmann D, Villiger L, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol 2021; 39: 949-957. 
213. Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021; 593: 429-434. 
214. Xu F, Zheng C, Xu W, Zhang S, Liu S, Chen X, et al. Breaking genetic shackles: The advance of base editing in genetic disorder  treatment. Front Pharmacol 2024; 15: 1364135-1364174. 
215. Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 2018; 19: 770-788. 
216. Wang K, Ning S, Zhang S, Jiang M, Huang Y, Pei H, et al. Extracellular matrix stiffness regulates colorectal cancer progression via HSF4. J Exp Clin Cancer Res 2025; 44: 30-51. 
217. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31: 827-832. 
218. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 2014; 32: 670-676. 
219. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9  nuclease specificity. Nat Biotechnol 2013; 31: 839-843. 
220. Li S, Liu L, Sun W, Zhou X, Zhou H. A large-scale genome and transcriptome sequencing analysis reveals the mutation  landscapes induced by high-activity adenine base editors in plants. Genome Biol 2022; 23: 51-69. 
221. Koblan LW, Doman JL, Wilson C, Levy JM, Tay T, Newby GA, et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol 2018; 36: 843-846. 
222. Zafra MP, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol 2018; 36: 888-893. 
223. Lee S, Ding N, Sun Y, Yuan T, Li J, Yuan Q, et al. Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome- and transcriptome-wide off-target effects. Sci Adv 2020; 6: eaba1773-1785. 
224. Thuronyi BW, Koblan LW, Levy JM, Yeh W-H, Zheng C, Newby GA, et al. Continuous evolution of base editors with expanded target compatibility and improved activity. Nat Biotechnol 2019; 37: 1070-1079. 
225. Komor AC, Zhao KT, Packer MS, Gaudelli NM, Waterbury AL, Koblan LW, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C: G-to-T: A base editors with higher efficiency and product purity. Sci Adv 2017; 3: eaao4774-4783. 
226. Ma Y, Zhang J, Yin W, Zhang Z, Song Y, Chang X. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat Methods 2016; 13: 1029-1035. 
227. Liu Z, Chen S, Shan H, Jia Y, Chen M, Song Y, et al. Precise base editing with CC context-specificity using engineered human  APOBEC3G-nCas9 fusions. BMC Biol 2020; 18: 111-125. 
228. Liu Z, Shan H, Chen S, Chen M, Zhang Q, Lai L, et al. Improved base editor for efficient editing in GC contexts in rabbits with an  optimized AID-Cas9 fusion. FASEB J 2019; 33: 9210-9219. 
229. Liu LD, Huang M, Dai P, Liu T, Fan S, Cheng X, et al. Intrinsic nucleotide preference of diversifying base editors guides antibody ex vivo affinity maturation. Cell Rep 2018; 25: 884-892. 
230. Zhang X, Chen L, Zhu B, Wang L, Chen C, Hong M, et al. Increasing the efficiency and targeting range of cytidine base editors through  fusion of a single-stranded DNA-binding protein domain. Nat Cell Biol 2020; 22: 740-750. 
231. Huang TP, Heins ZJ, Miller SM, Wong BG, Balivada PA, Wang T, et al. High-throughput continuous evolution of compact Cas9 variants targeting  single-nucleotide-pyrimidine PAMs. Nat Biotechnol 2023; 41: 96-107. 
232. Schmidheini L, Mathis N, Marquart KF, Rothgangl T, Kissling L, Böck D, et al. Continuous directed evolution of a compact CjCas9 variant with broad PAM compatibility. Nat Chem Biol 2024; 20: 333-343. 
233. Chatterjee P, Jakimo N, Lee J, Amrani N, Rodríguez T, Koseki SRT, et al. An engineered ScCas9 with broad PAM range and high specificity and activity. Nat Biotechnol 2020; 38: 1154-1158. 
234. Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 2020; 38: 883-891. 
235. Gaudelli NM, Lam DK, Rees HA, Solá-Esteves NM, Barrera LA, Born DA, et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol 2020; 38: 892-900. 
236. Tycko J, Van M V, Aradhana, DelRosso N, Ye H, Yao D, et al. Development of compact transcriptional effectors using high-throughput measurements in diverse contexts. Nat Biotechnol 2024; 10: 1038.
237. He Y, Zhou X, Chang C, Chen G, Liu W, Li G, et al. Protein language models-assisted optimization of a uracil-N-glycosylase variant enables programmable T-to-G and T-to-C base editing. Mol Cell 2024; 84: 1257-1270.
238. Luan F, Cui Y, Huang R, Yang Z, Qiao S. Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk  factor and its potential prognostic value in SKCM. Sci Rep 2025; 15: 3223-3245. 
239. Jin S, Lin Q, Luo Y, Zhu Z, Liu G, Li Y, et al. Genome-wide specificity of prime editors in plants. Nat Biotechnol 2021; 39: 1292-1299. 
240.  Lin J, Liu X, Lu Z, Huang S, Wu S, Yu W, et al. Modeling a cataract disorder in mice with prime editing. Mol Ther Nucleic Acids 2021; 25: 494-501. 
241. Gao P, Lyu Q, Ghanam AR, Lazzarotto CR, Newby GA, Zhang W, et al. Prime editing in mice reveals the essentiality of a single base in driving  tissue-specific gene expression. Genome Biol 2021; 22: 83-104. 
242. Liu Y, Li X, He S, Huang S, Li C, Chen Y, et al. Efficient generation of mouse models with the prime editing system. Cell Discov 2020; 6: 27-31. 
243. Gao R, Fu Z-C, Li X, Wang Y, Wei J, Li G, et al. Genomic and transcriptomic analyses of prime editing guide RNA-independent  off-target effects by prime editors. Cris J 2022; 5: 276-293. 
244. Schene IF, Joore IP, Oka R, Mokry M, van Vugt AHM, van Boxtel R, et al. Prime editing for functional repair in patient-derived disease models. Nat Commun 2020; 11: 5352-5360. 
245. Geurts MH, de Poel E, Pleguezuelos-Manzano C, Oka R, Carrillo L, Andersson-Rolf A, et al. Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in  organoids. Life Sci Alliance 2021; 4: e202000940-e202000952. 
246. Feng Y, Liu S, Mo Q, Liu P, Xiao X, Ma H. Enhancing prime editing efficiency and flexibility with tethered and split  pegRNAs. Protein Cell 2023; 14: 304-308. 
247. Liu B, Dong X, Cheng H, Zheng C, Chen Z, Rodríguez TC, et al. A split prime editor with untethered reverse transcriptase and circular RNA  template. Nat Biotechnol 2022; 40: 1388-1393. 
248.  Li X, Zhou L, Gao B-Q, Li G, Wang X, Wang Y, et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat Commun 2022; 13: 1669-1678. 
249.  Liu Y, Yang G, Huang S, Li X, Wang X, Li G, et al. Enhancing prime editing by Csy4-mediated processing of pegRNA. Vol. 31, Cell research. England; 2021. p. 1134–1136. 
250.  Nelson JW, Randolph PB, Shen SP, Everette KA, Chen PJ, Anzalone A V, et al. Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol 2022; 40: 402-410. 
251.  Atefi A, Ghanaatpisheh A, Ghasemi A, Haghshenas H, Eyvani K, Bakhshi A, et al. Meningitis after COVID-19 vaccination, a systematic review of case reports and case series. BMC Infect Dis  2024; 24: 1138-1162.
252. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016; 351: 84-88. 
253. Kim D, Lim K, Kim S-T, Yoon S-H, Kim K, Ryu S-M, et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol 2017; 35: 475-480. 
254. Wan T, Chen Y, Pan Q, Xu X, Kang Y, Gao X, et al. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of  Cas9 ribonucleoprotein for colorectal cancer therapy. J Control Release 2020; 322: 236-247. 
255. Blanas A, Cornelissen LAM, Kotsias M, van der Horst JC, van de Vrugt HJ, Kalay H, et al. Transcriptional activation of fucosyltransferase (FUT) genes using the  CRISPR-dCas9-VPR technology reveals potent N-glycome alterations in colorectal cancer cells. Glycobiology 2019; 29: 137-150. 
256. Hsu DS, Kornepati AV, Glover W, Kennedy EM, Cullen BR. Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo. Future Virol 2018; 13: 475-482. 
257. Mingozzi F, High KA. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 2013; 122: 23-36. 
258. Li T, Liu D, Lei X, Jiang Q. Par3L enhances colorectal cancer cell survival by inhibiting Lkb1/AMPK signaling pathway. Biochem Biophys Res Commun 2017; 482: 1037-1041. 
259. Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, et al. Revolutionizing cancer treatment: Enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol 2024; 15: 1354825-1354836. 
260. Samareh Salavatipour M, Poursalehi Z, Hosseini Rouzbahani N, Mohammadyar S, Vasei M. CRISPR-Cas9 in basic and translational aspects of cancer therapy. Bioimpacts 2024; 14: 30087-30108. 
261. Yang Z, Liu X, Xu H, Teschendorff AE, Xu L, Li J, et al. Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma. Commun Biol 2024; 7: 824-844. 
262. Zhen S, Li X. Liposomal delivery of CRISPR/Cas9. Cancer Gene Ther 2020; 27: 515-527. 
263. Ashok B, Peppas NA, Wechsler ME. Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9. J Drug Deliv Sci Technol 2021; 65: 102728-102756. 
264. Wang P, Zhang L, Xie Y, Wang N, Tang R, Zheng W, et al. Genome editing for cancer therapy: Delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier. Adv Sci (Weinh) 2017; 4: 1700175-1700185. 
265. Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 2016; 17: 300-312. 
266. Koonin EV, Makarova KS. Anti-CRISPRs on the march. Science 2018; 362: 156-157. 
267. Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 2015; 4: e264-272. 
268. Guo Z, Guan K, Bao M, He B, Lu J. LINC-PINT plays an anti-tumor role in nasopharyngeal carcinoma by binding to  XRCC6 and affecting its function. Pathol Res Pract 2024; 260: 155460. 
269. Nie Y, Li D, Peng Y, Wang S, Hu S, Liu M, et al. Metal organic framework coated MnO(2) nanosheets delivering doxorubicin and  self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm 2020; 585: 119513. 
270. Le QA, Wittayarat M, Namula Z, Lin Q, Takebayashi K, Hirata M, et al. Multiple gene editing in porcine embryos using a combination of microinjection, electroporation, and transfection methods. Vet world 2022; 15: 2210-2216. 
271. Xu X, Wan T, Xin H, Li D, Pan H, Wu J, et al. Delivery of CRISPR/Cas9 for therapeutic genome editing. J Gene Med 2019; 21: e3107. 
272. Horii T, Hatada I. Generation of genome-edited mice by cytoplasmic injection of CRISPR-Cas9 RNA. Methods Mol Biol 2023; 2637: 75-86. 
273. Firuzpour F, Saleki K, Aram C, Rezaei N. Nanocarriers in glioblastoma treatment: A neuroimmunological perspective. Rev Neurosci 2024; 36: 431-453.
274. Hu W, Yang Y, Qi L, Chen J, Ge W, Zheng S. Subtyping of microsatellite instability-high colorectal cancer. Cell Commun Signal 2019; 17: 79-89. 
275. Kleiderman E, Ogbogu U. Realigning gene editing with clinical research ethics: What the “CRISPR Twins”  debacle means for Chinese and international research ethics governance. Account Res 2019; 26: 257-264. 
276. Li C, Du X, Zhang H, Liu S. Knockdown of ribosomal protein L22-like 1 arrests the cell cycle and promotes  apoptosis in colorectal cancer. Cytojournal 2024; 21: 45. 
277. Muhammad Rafid AH, Toufikuzzaman M, Rahman MS, Rahman MS. CRISPRpred(SEQ): A sequence-based method for sgRNA on target activity prediction using traditional machine learning. BMC Bioinformatics 2020; 21: 223-236. 
278. Qian FC, Zhou LW, Li YY, Yu ZM, Li LD, Wang YZ, et al. SEanalysis 2.0: A comprehensive super-enhancer regulatory network analysis tool  for human and mouse. Nucleic Acids Res 2023; 51: W520-527. 
279. Abbasi AF, Asim MN, Dengel A. Transitioning from wet lab to artificial intelligence: a systematic review of AI  predictors in CRISPR. J Transl Med 2025; 23: 153-199. 
280. Liang L, Liang X, Yu X, Xiang W. Bioinformatic analyses and integrated machine learning to predict prognosis and  therapeutic response based on E3 ligase-related genes in colon cancer. J Cancer 2024; 15: 5376-5395.